BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
W Mills, R Chopra, A McMillan, R Pearce… - Journal of Clinical …, 1995 - ascopubs.org
PURPOSE To evaluate the outcome of patients with relapsed or resistant non-Hodgkin's
lymphoma (NHL) undergoing high-dose chemotherapy and autologous bone marrow …
lymphoma (NHL) undergoing high-dose chemotherapy and autologous bone marrow …
BeEAM (bendamustine, etoposide, cytarabine, melphalan) versus BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning regimen before autologous …
R Wu, L Ma - Cell Transplantation, 2023 - journals.sagepub.com
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
In many stem cell transplant centres, BCNU, etoposide, cytarabine and melphalan (BEAM)
high-dose chemotherapy (HDCT) has been replaced by the more economic and available …
high-dose chemotherapy (HDCT) has been replaced by the more economic and available …
淋巴瘤自体造血干细胞移植中苯达莫司汀, 依托泊苷, 阿糖胞苷, 美法仑(BeEAM) 预处理方案的安全性
孔黛， 王新凯， 裴晓杭， 连成， 牛晓娜， 白炎亮， 牛俊伟… - 中国组织工程研究, 2023 - cjter.com
淋巴瘤自体造血干细胞移植中苯达莫司汀,依托泊苷,阿糖胞苷,美法仑(BeEAM) 预处理方案的安
Page 1 Chinese Journal of Tissue Engineering Research|Vol 27|No.19|July 2023|2975 中国 …
Page 1 Chinese Journal of Tissue Engineering Research|Vol 27|No.19|July 2023|2975 中国 …
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial
F Keil, AMS Müller, A Berghold, R Riedl… - …, 2023 - thelancet.com
Background Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide,
cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell …
cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell …
[HTML][HTML] Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a …
NI AlJohani, M Nasani, HE Ahmed, JU Rehman… - … /Oncology and Stem Cell …, 2021 - Elsevier
BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan)
has been widely used for autologous stem cell transplantation in patients with relapsed or …
has been widely used for autologous stem cell transplantation in patients with relapsed or …
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for …
MÉ Plante, X Feng, JS Boudreault - Leukemia & Lymphoma, 2023 - Taylor & Francis
One of the most widely accepted conditioning regimens for hematopoietic stem cell
transplantation (HSCT) is BEAM (carmustine, etoposide, cytarabine, melphalan). However, a …
transplantation (HSCT) is BEAM (carmustine, etoposide, cytarabine, melphalan). However, a …
Conditioning regimens: balancing efficacy and toxicity
TR Brooks, D Jagadeesh - Leukemia & Lymphoma, 2023 - Taylor & Francis
The remarkable evolution of hematopoietic stem cell transplant (HSCT) over the years
driven by the advances in donor selection, conditioning regimen, supportive care, GVHD …
driven by the advances in donor selection, conditioning regimen, supportive care, GVHD …
[HTML][HTML] Evaluating the Efficacy of Modified BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell …
M Ramzi, E Vafaie, H Haghighinejad… - International Journal of …, 2023 - ncbi.nlm.nih.gov
Background: High-dose chemotherapy followed by Autologous SCT (stem cell
transplantation) is a treatment of choice for relapsed and refractory lymphoma. Due to cost …
transplantation) is a treatment of choice for relapsed and refractory lymphoma. Due to cost …
Evaluation of outcome and safety profile in high-dose BEAM and Benda-EAM chemotherapy with subsequent autologous stem cell transplantation in lymphoma …
K Krawiec, P Strzałka, O Racińska, M Kędzior… - Contemporary Oncology … - termedia.pl
Results: During the post-HSCT period 58% of patients experienced febrile neutropenia
(51.3% vs. 64.3% in BEAM and BeEAM, respectively; p= 0.27), 80.5% mucositis (69.2% vs …
(51.3% vs. 64.3% in BEAM and BeEAM, respectively; p= 0.27), 80.5% mucositis (69.2% vs …